- Home
- AIM vs DEVS Comparison
AIM vs DEVS Comparison
Compare AIM & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- DEVS
- Stock Information
- Founded
- AIM 1966
- DEVS N/A
- Country
- AIM United States
- DEVS Canada
- Employees
- AIM N/A
- DEVS N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- DEVS
- Sector
- AIM Health Care
- DEVS
- Exchange
- AIM Nasdaq
- DEVS NYSE
- Market Cap
- AIM 15.9M
- DEVS 16.5M
- IPO Year
- AIM N/A
- DEVS N/A
- Fundamental
- Price
- AIM $0.21
- DEVS $0.66
- Analyst Decision
- AIM Strong Buy
- DEVS
- Analyst Count
- AIM 2
- DEVS 0
- Target Price
- AIM $2.75
- DEVS N/A
- AVG Volume (30 Days)
- AIM 672.1K
- DEVS 2.4M
- Earning Date
- AIM 11-15-2024
- DEVS 02-12-2025
- Dividend Yield
- AIM N/A
- DEVS N/A
- EPS Growth
- AIM N/A
- DEVS N/A
- EPS
- AIM N/A
- DEVS N/A
- Revenue
- AIM $190,000.00
- DEVS N/A
- Revenue This Year
- AIM N/A
- DEVS N/A
- Revenue Next Year
- AIM $1,693.10
- DEVS N/A
- P/E Ratio
- AIM N/A
- DEVS N/A
- Revenue Growth
- AIM N/A
- DEVS N/A
- 52 Week Low
- AIM $0.16
- DEVS $0.48
- 52 Week High
- AIM $0.62
- DEVS $1.91
- Technical
- Relative Strength Index (RSI)
- AIM 50.86
- DEVS N/A
- Support Level
- AIM $0.19
- DEVS N/A
- Resistance Level
- AIM $0.23
- DEVS N/A
- Average True Range (ATR)
- AIM 0.02
- DEVS 0.00
- MACD
- AIM -0.00
- DEVS 0.00
- Stochastic Oscillator
- AIM 48.29
- DEVS 0.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.